Could internal limiting membrane peeling before Voretigen neparvovec-ryzl subretinal injection prevent focal chorioretinal atrophy?
Author:
Dormegny LeaORCID,
Studer Fouzia,
Sauer Arnaud,
Ballonzoli Laurent,
Speeg-Schatz Claude,
Bourcier TristanORCID,
Dollfus Helene,
Gaucher David
Subject
Multidisciplinary
Reference12 articles.
1. Leber congenital amaurosis;Tsang;Adv. Exp. Med. Biol.,2018
2. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics;Cideciyan;Proc. Natl. Acad. Sci. U. S. A.,2008
3. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial;Russell;Lancet,2017
4. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials;Maguire;Ophthalmology,2019
5. Retinal pigment epithelium atrophy after subretinal voretigene neparvovec-rzyl for RPE65-related disease: a 6-month follow-up;Giansanti;Retina,2022